Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 329 - 336 of 12092 results
Mintz on Air: Practical Policies - Performance Evaluations
February 25, 2025| Podcast| Viewpoint
Navigating Changing Immigration Policies: Workplace Implications
February 25, 2025| Blog| Viewpoint
The Litigators on The American Lawyer’s Top Lateral Hires List
February 25, 2025| News
Federal Court Temporarily Halts Implementation of Portions of President Trump’s DEI-Related Executive Orders
February 24, 2025| Blog| Viewpoint
Patenting AI/ML Life Sciences and TechBio Innovations – How Much Disclosure is Sufficient?
February 24, 2025| Blog| Viewpoint
Canadian Software Could Be in Donald Trump’s Sights for Tariffs, Technology Lawyers Warn
February 23, 2025| News
Session-Replay Class Action Tossed by the Eighth Circuit
February 21, 2025| Blog| Viewpoint
The Changing Landscape of Privacy Class Actions in 2025
February 21, 2025| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|